posted on 2021-08-09, 11:35authored byTianyu Han, Yuying Wu, Weinan Han, Kaiwen Yan, Jian Zhao, Yanyan Sun
The facile modification of the ligands
in organometallic Ru(II)–arene
complexes offers more opportunities to optimize their pharmacological
profiles. Herein, three Ru(II)–arene complexes containing a
glutathione S-transferase (GST) inhibitor (NBDHEX)
in chelate ligand have been designed and synthesized in this study.
In vitro results indicated that the ligation with NBDHEX significantly
increased the activities and selectivities of the organometallic Ru(II)–arene
complexes against tumor cells, especially complex 3,
which was the most active compound among the tested compounds. DFT
calculations and hydrolysis results demonstrated that complex 3 with more alkyl groups in the arene ligand has increased
electron density at the Ru(II) center as compared with complexes 1 and 2, thus resulting in the improved hydrolysis
rate, which may be responsible for its higher anticancer activity.
Further studies showed that complexes 1–3 can cause the loss of the mitochondrial membrane potential
and upregulate the expression of Bcl-2 and Bax in A549 cells, suggesting
that complexes 1–3-induced cell death
may be mediated via the mitochondrial apoptotic pathway. Thus, these
findings suggested that simultaneous modification of the chelate ligands
and arene rings in the organometallic Ru(II)–arene complexes
is an effective way to improve their pharmacological properties.